Argent Biopharma Ltd (fra:H5O0) Share Price

Company Profile

Business description
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Contact
295 Rokeby Road
Suite 1
SubiacoWA6008
AUS
T: +61 865552950
E: [email protected]
https://www.argentbiopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2027
Employees

Recommended

We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.

Brian Colello, CPA | 24 August 2026

Profits flatten as airport ramps up redevelopment.

Angus Hewitt, CFA | 24 August 2026

Income appeal backed by growth projects.

Adrian Atkins | 24 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,316.70	9.20	0.10%
CAC 40	8,487.11	2.68	0.03%
DAX 40	26,150.17	13.61	0.05%
Dow JONES (US)	53,277.01	517.80	0.98%
FTSE 100	10,840.32	23.76	0.22%
HKSE	25,517.33	492.13	-1.89%
NASDAQ	26,180.46	113.29	0.43%
Nikkei 225	65,528.09	488.27	-0.74%
NZX 50 Index	13,881.88	90.78	-0.65%
S&P 500	7,674.37	33.21	0.43%
S&P/ASX 200	9,103.10	9.90	0.11%
SSE Composite Index	3,882.01	23.19	-0.59%